Related references
Note: Only part of the references are listed.FGF23 induced left ventricular hypertrophy mediated by FGFR4 signaling in the myocardium is attenuated by soluble Klotho in mice
Xiaobin Han et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2020)
Acquired long QT syndrome in chronic kidney disease patients
Peng Liu et al.
RENAL FAILURE (2020)
Trimethylamine-N-oxide acutely increases cardiac muscle contractility
Carlee Oakley et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2020)
Enhanced Klotho availability protects against cardiac dysfunction induced by uraemic cardiomyopathy by regulating Ca2+handling
Jose Alberto Navarro-Garcia et al.
BRITISH JOURNAL OF PHARMACOLOGY (2020)
Arrhythmias and Sudden Cardiac Death in End Stage Renal Disease: Epidemiology, Risk Factors, and Management
Rahul Samanta et al.
CANADIAN JOURNAL OF CARDIOLOGY (2019)
First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma
Richard D. Kim et al.
CANCER DISCOVERY (2019)
FGFR4 does not contribute to progression of chronic kidney disease
Ashlee Taylor et al.
SCIENTIFIC REPORTS (2019)
Fibroblast growth factor-23 promotes rhythm alterations and contractile dysfunction in adult ventricular cardiomyocytes
Jose Alberto Navarro-Garcia et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2019)
Changes in QTc interval in long-term hemodialysis patients
Yoshihiro Matsumoto et al.
PLOS ONE (2019)
Increased FGF23 protects against detrimental cardio-renal consequences during elevated blood phosphate in CKD
Erica L. Clinkenbeard et al.
JCI INSIGHT (2019)
Fibroblast growth factor 23 does not directly influence skeletal muscle cell proliferation and differentiation or ex vivo muscle contractility
Keith G. Avin et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2018)
Vitamin D treatment attenuates cardiac FGF23/FGFR4 signaling and hypertrophy in uremic rats
Maren Leifheit-Nestler et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2017)
Is Fibroblast growth factor 23 the leading cause of increased mortality among chronic kidney disease patients? A narrative review
Usama A. A. Sharaf El Din et al.
JOURNAL OF ADVANCED RESEARCH (2017)
FGF23/FGFR4-mediated left ventricular hypertrophy is reversible
Alexander Grabner et al.
SCIENTIFIC REPORTS (2017)
Calcium Signaling and Cardiac Arrhythmias
Andrew P. Landstrom et al.
CIRCULATION RESEARCH (2017)
Induction of cardiac FGF23/FGFR4 expression is associated with left ventricular hypertrophy in patients with chronic kidney disease
Maren Leifheit-Nestler et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2016)
Prevalence and risk factors for prolonged QT interval and QT dispersion in patients with type 2 diabetes
Vladan M. Ninkovic et al.
ACTA DIABETOLOGICA (2016)
Prognostic value of FGF23 among patients with end-stage renal disease: a systematic review and meta-analysis
Hongliu Yang et al.
BIOMARKERS IN MEDICINE (2016)
Fibroblast growth factor 23 directly targets hepatocytes to promote inflammation in chronic kidney disease
Saurav Singh et al.
KIDNEY INTERNATIONAL (2016)
Fibroblast growth factor 23 dysregulates late sodium current and calcium homeostasis with enhanced arrhythmogenesis in pulmonary vein cardiomyocytes
Shih-Yu Huang et al.
ONCOTARGET (2016)
Skeletal Muscle, but not Cardiovascular Function, Is Altered in a Mouse Model of Autosomal Recessive Hypophosphatemic Rickets
Michael J. Wacker et al.
FRONTIERS IN PHYSIOLOGY (2016)
Association of Fibroblast Growth Factor 23 With Atrial Fibrillation in Chronic Kidney Disease, From the Chronic Renal Insufficiency Cohort Study
Rupal Mehta et al.
JAMA CARDIOLOGY (2016)
Stochastic spontaneous calcium release events trigger premature ventricular complexes by overcoming electrotonic load
Fernando O. Campos et al.
CARDIOVASCULAR RESEARCH (2015)
Activation of Cardiac Fibroblast Growth Factor Receptor 4 Causes Left Ventricular Hypertrophy
Alexander Grabner et al.
CELL METABOLISM (2015)
Circulating Fibroblast Growth Factor 23 Has a U-Shaped Association With Atrial Fibrillation Prevalence
Masatoshi Miyamura et al.
CIRCULATION JOURNAL (2015)
Cause of Death in Patients with Reduced Kidney Function
Stephanie Thompson et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2015)
United States Renal Data System public health surveillance of chronic kidney disease and end-stage renal disease
Allan J. Collins et al.
KIDNEY INTERNATIONAL SUPPLEMENTS (2015)
FGF23 directly impairs endothelium-dependent vasorelaxation by increasing superoxide levels and reducing nitric oxide bioavailability
Neerupma Silswal et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2014)
FGF-23 dysregulates calcium homeostasis and electrophysiological properties in HL-1 atrial cells
Yu-Hsun Kao et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2014)
Pathogenesis of Arrhythmias in a Model of CKD
Chia-Hsiang Hsueh et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2014)
Incident Atrial Fibrillation and Risk of Death in Adults With Chronic Kidney Disease
Nisha Bansal et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2014)
Cardiovascular Pathophysiology in Chronic Kidney Disease: Opportunities to Transition from Disease to Health
Matthew I. Tomey et al.
ANNALS OF GLOBAL HEALTH (2014)
FGF23 is a novel regulator of intracellular calcium and cardiac contractility in addition to cardiac hypertrophy
Chad D. Touchberry et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2013)
Higher fibroblast growth factor-23 increases the risk of all-cause and cardiovascular mortality in the community
Johan Arnlov et al.
KIDNEY INTERNATIONAL (2013)
Intact fibroblast growth factor 23 levels predict incident cardiovascular event before but not after the start of dialysis
Chikako Nakano et al.
BONE (2012)
FGF23 neutralization improves chronic kidney disease-associated hyperparathyroidism yet increases mortality
Victoria Shalhoub et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010
Rafael Lozano et al.
LANCET (2012)
Relationship of serum fibroblast growth factor 23 with cardiovascular disease in older community-dwelling women
Mansi Dalal et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2011)
FGF23 induces left ventricular hypertrophy
Christian Faul et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Inhibition of Thromboxane A(2)-Induced Arrhythmias and Intracellular Calcium Changes in Cardiac Myocytes by Blockade of the Inositol Trisphosphate Pathway
M. J. Wacker et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2009)
Benchmarking Ventricular Arrhythmias in the Mouse-Revisiting the 'Lambeth Conventions' 20 Years On
Catherine E. Huggins et al.
HEART LUNG AND CIRCULATION (2008)
Emerging roles of inositol 1,4,5-trisphosphate signaling in cardiac myocytes
Jens Kockskaemper et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2008)
FGFR3 and FGFR4 Do not Mediate Renal Effects of FGF23
Shiguang Liu et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2008)
FGFR4 prevents hyperlipidemia and insulin resistance but underlies high-fat diet-induced fatty liver
Xinqiang Huang et al.
DIABETES (2007)
Dominant negative suppression of rad leads to QT prolongation and causes ventricular arrhythmias via modulation of L-type Ca2+ channels in the heart
Hirotaka Yada et al.
CIRCULATION RESEARCH (2007)
Prevalence and predictors of arrhythmia in end stage renal disease patients on hemodialysis
Huseyin Bozbas et al.
RENAL FAILURE (2007)
Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism
Jian Q. Feng et al.
NATURE GENETICS (2006)
Thromboxane A2-induced arrhythmias in the anesthetized rabbit
MJ Wacker et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2006)
Studying cardiac arrhythmias in the mouse - A reasonable model for probing mechanisms?
JM Nerbonne
TRENDS IN CARDIOVASCULAR MEDICINE (2004)
FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis
T Shimada et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2004)
Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism
T Shimada et al.
JOURNAL OF CLINICAL INVESTIGATION (2004)
Mouse isolated perfused heart: Characteristics and cautions
FJ Sutherland et al.
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY (2003)
Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers
T Larsson et al.
KIDNEY INTERNATIONAL (2003)
Increased carbon tetrachloride-induced liver injury and fibrosis in FGFR4-deficient mice
CD Yu et al.
AMERICAN JOURNAL OF PATHOLOGY (2002)
Sarcoplasmic reticulum Ca2+ release causes myocyte depolarization -: Underlying mechanism and threshold for triggered action potentials
K Schlotthauer et al.
CIRCULATION RESEARCH (2000)
Elevated cholesterol metabolism and bile acid synthesis in mice lacking membrane tyrosine kinase receptor FGFR4
CD Yu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Share Paper
